Skip to content

Water-injecting Endoscopic Submucosal Dissection for Early Gastric Cancer: a Retrospective Cohort Study

Water-injecting Endoscopic Submucosal Dissection for Early Gastric Cancer: a Retrospective Cohort Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07244471
Enrollment
548
Registered
2025-11-24
Start date
2019-01-01
Completion date
2024-12-31
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Gastric Cancer, Endoscopic Resection

Keywords

Endoscopic resection, Early gastric cancer

Brief summary

Endoscopic submucosal dissection (ESD) is a technically difficult and time-consuming procedure. Several water-jet knives have been developed to address this issue. The aim of this study was to develop a new ESD method using continuous low-pressure water injection at 1-2 atmosphere with a tip-injected electric knife while dissection simultaneous cutting, dissection, electrocoagulation, and hemostasis, which was so called as water-injecting ESD (W-ESD) to treat early gastric cancer and compare the efficacy and safety with conventional methods.

Interventions

None listed

Sponsors

Shanghai East Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. age ≥ 18 years; 2. histologically proven early gastric adenocarcinoma; 3. meeting the absolute or expanded indication for ESD according to the Japanese gastric cancer treatment guidelines 2021 ; 4. Eastern Cooperative Oncology Group performance status ≤ 2; 5. adequate hematological function (hemoglobin ≥ 9 g/dL, platelets ≥ 50 000/mm3,international normalized ratio\<1.5); 6. sufficient renal function (serum creatinine ≤ 2.0 mg/dL); and (7) adequate hepatic function (serum aspartate aminotransferase ≤ 100 IU/L, serum alanine aminotransferase ≤ 100 IU/L).

Exclusion criteria

1. pregnancy or breastfeeding; 2. difficulty obtaining consent due to psychiatric disorder; 3. multiple lesions; 4. history of gastrectomy or gastrointestinal reconstruction surgery.

Design outcomes

Primary

MeasureTime frameDescription
Total procedure timeImmediately after surgeryAverage time to complete endoscopic resection
Circumferential incision timeImmediately after surgeryAverage time for APC labeling of the lesion margin during circumferential incision
Dissection timeImmediately after surgeryAverage time to complete endoscopic dissection
Dissection speedImmediately after surgeryAverage speed of endoscopic dissection

Secondary

MeasureTime frameDescription
Completeness of en bloc resectionImmediately after surgeryNumber of patients with complete lesion resection / Total number of subjects
Adverse event rateImmediately after surgery and one month post-surgeryThe proportion of adverse events occurring in subjects following surgery (though not necessarily causally related to treatment), encompassing perforation complications, myomere injuries, intraoperative blood loss, thermocoagulation forceps replacements, delayed bleeding, and delayed perforation.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026